Systematic assessment of Tolvaptan in cirrhosis: Implications for clinical practice

Summaries 2 min 835

Font Size

Created On: 30/12/2023

A systematic review and meta-analysis of randomized controlled trials (RCTs) aimed to assess the effectiveness and safety of Tolvaptan in the context of cirrhosis.

See All

Key take away

In cirrhotic patients with ascites showing insufficient response to standard diuretics or experiencing hyponatremia, the short-term application of Tolvaptan could be contemplated.

Background

A systematic review and meta-analysis of randomized controlled trials (RCTs) aimed to assess the effectiveness and safety of Tolvaptan in the context of cirrhosis.

Method

A thorough search of PubMed, EMBASE, and the Cochrane Library databases was conducted to locate RCTs assessing the effectiveness and/or safety of Tolvaptan in cirrhosis. Calculations were performed for risk ratios (RRs) and weighted mean differences (WMDs), and the occurrence of commonly observed adverse events (AEs) was aggregated.

Result

Overall, 8 RCTs were incorporated in the analysis. Tolvaptan demonstrated a significant association with increased rates of ascites improvement (RR = 1.49) and hyponatremia improvement (RR = 1.80), as well as a higher occurrence of any AEs (RR = 1.18), though not serious AEs (RR = 0.86).

Tolvaptan was substantially linked to a decline in body weight (WMD = −1.30 kg) and abdominal circumference (WMD = −1.71 cm), along with elevation in daily urine volume (WMD = 1299.84 mL) and serum sodium concentration (WMD = 2.57 mmol/L). The pooled incidences of pollakiuria, constipation, thirst, and dry mouth, were 17%, 6%, 24%, and 16%, respectively.

Conclusion

Tolvaptan's short-term use was considered favorable for cirrhotic patients with ascites who do not respond adequately to conventional diuretics, as well as for those having hyponatremia.